EN | RU
EN | RU

Help Support

Back

Teneligliptin therapy in nondiabetic obesity: GLP-1 enhancement and metabolic benefits

Obesity Obesity
Obesity Obesity

This randomized, prospective, double-blind, placebo-controlled, parallel-group study determined the impact of administering 20 mg Teneligliptin (oral antidiabetic agent) twice daily in conjunction with a low carbohydrate diet and regular physical exercise in obese individuals without diabetes.

See All

Key take away

In non-diabetic obese individuals, using 20 mg twice daily Teneligliptin is well-tolerated and remarkably improves GLP-1 levels, and reduces insulin resistance, body weight, triglyceride, appetite, and metabolic syndrome.

Background

This randomized, prospective, double-blind, placebo-controlled, parallel-group study determined the impact of administering 20 mg Teneligliptin (oral antidiabetic agent) twice daily in conjunction with a low carbohydrate diet and regular physical exercise in obese individuals without diabetes.

Method

At an outpatient department of an endocrinology hospital, the study was carried out over a period of forty-eight weeks. Overall, 150 nondiabetic obese volunteers were randomly allocated into:

  • Test group (n=75): Received 20 mg Teneligliptin twice daily thirty minutes prior to meals (along with a low carbohydrate diet and regular physical exercise)
  • Control group (n=75): Received placebo twice daily thirty minutes prior to meals (along with a low carbohydrate diet and regular physical exercise)

Result

At the end of forty-eight weeks, remarkable improvements were observed in body weight, glucagon-like peptide-1 (GLP-1) levels, simplified nutrition assessment questionnaire (SNAQ) scores, homeostasis model assessment of insulin resistance (HOMA-IR), and triglyceride levels. The mean differences and 95% confidence intervals for GLP-1 (pg/mL) were 76.42 (44.42-148.41) (P = 0.37); SNAQ score, -1.64 (-2.48 to -0.81) (P = 0.000); HOMA-IR, -0.9 (-0.59 to -0.38) (P = 0.000); triglycerides (mg/dL), -29.37 (-44.46 to -14.07) (P = 0.000); and reduction in body weight (kilograms), -3.09 (-6.11 to -0.07) (P = 0.043).

Conclusion

Treatment with Teneligliptin resulted in vital improvements in GLP-1 levels, decreased insulin resistance, body weight, metabolic syndrome markers, triglyceride levels, and appetite. It was generally well-tolerated, except for instances of upper respiratory tract infections.

Source:

Metabolic Syndrome and Related Disorders

Article:

Effect of Teneligliptin 20 mg Twice Daily on Glucagon-Like Peptide-1 Levels and Its Influence on Non-Glycemic Components in Non-Diabetic Obese Individuals

Authors:

Ranakishor Pelluri et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: